DE69840403D1 - System zum transfer und zur expression von heterologen genen ins knochenmark in vivo - Google Patents
System zum transfer und zur expression von heterologen genen ins knochenmark in vivoInfo
- Publication number
- DE69840403D1 DE69840403D1 DE69840403T DE69840403T DE69840403D1 DE 69840403 D1 DE69840403 D1 DE 69840403D1 DE 69840403 T DE69840403 T DE 69840403T DE 69840403 T DE69840403 T DE 69840403T DE 69840403 D1 DE69840403 D1 DE 69840403D1
- Authority
- DE
- Germany
- Prior art keywords
- bone marrow
- infectious
- disclosed
- virus
- heterologic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/36011—Togaviridae
- C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
- C12N2770/36122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/36011—Togaviridae
- C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
- C12N2770/36141—Use of virus, viral particle or viral elements as a vector
- C12N2770/36143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Veterinary Medicine (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/801,263 US5811407A (en) | 1997-02-19 | 1997-02-19 | System for the in vivo delivery and expression of heterologous genes in the bone marrow |
PCT/US1998/002945 WO1998036779A2 (en) | 1997-02-19 | 1998-02-18 | System for the in vivo delivery and expression of heterologous genes in the bone marrow |
Publications (1)
Publication Number | Publication Date |
---|---|
DE69840403D1 true DE69840403D1 (de) | 2009-02-12 |
Family
ID=25180622
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE69840403T Expired - Lifetime DE69840403D1 (de) | 1997-02-19 | 1998-02-18 | System zum transfer und zur expression von heterologen genen ins knochenmark in vivo |
Country Status (8)
Country | Link |
---|---|
US (3) | US5811407A (de) |
EP (1) | EP0989863B1 (de) |
JP (1) | JP2001515348A (de) |
AT (1) | ATE419368T1 (de) |
AU (1) | AU749903B2 (de) |
CA (1) | CA2281858C (de) |
DE (1) | DE69840403D1 (de) |
WO (1) | WO1998036779A2 (de) |
Families Citing this family (52)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6015686A (en) * | 1993-09-15 | 2000-01-18 | Chiron Viagene, Inc. | Eukaryotic layered vector initiation systems |
US6451592B1 (en) * | 1996-04-05 | 2002-09-17 | Chiron Corporation | Recombinant alphavirus-based vectors with reduced inhibition of cellular macromolecular synthesis |
US20020147143A1 (en) | 1998-03-18 | 2002-10-10 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of lung cancer |
DE69927249T2 (de) * | 1998-03-27 | 2006-06-29 | Cytos Biotechnology Ag | Induzierendes alphavirengen- expressionssystem |
CA2336554A1 (en) * | 1998-06-29 | 2000-01-06 | U.S. Medical Research Institute Of Infectious Diseases | Marburg virus vaccines |
JP2002521461A (ja) | 1998-07-29 | 2002-07-16 | インビトロゲン・コーポレーション | Rnaウイルスを用いる組換えタンパク質の調節発現 |
EP1100944A1 (de) * | 1998-07-30 | 2001-05-23 | The Johns Hopkins University School Of Medicine | Zielgerichteter alphavirus und vektoren der alphavirus |
US20030235557A1 (en) | 1998-09-30 | 2003-12-25 | Corixa Corporation | Compositions and methods for WT1 specific immunotherapy |
US8647864B2 (en) * | 1999-04-14 | 2014-02-11 | Novartis Ag | Compositions and methods for generating an immune response utilizing alphavirus-based vector systems |
DE60044125D1 (de) * | 1999-04-14 | 2010-05-20 | Novartis Vaccines & Diagnostic | Zusammensetzungen und verfahren zur auslösung einer immunantwort auf basis alphavirus-vektoren-systeme |
AU1647501A (en) | 1999-12-10 | 2001-06-18 | Cytos Biotechnology Ag | Replicon based activation of endogenous genes |
DK1265915T3 (da) | 2000-02-23 | 2011-02-14 | Glaxosmithkline Biolog Sa | Nye forbindelser |
AU2001249380A1 (en) * | 2000-03-22 | 2001-11-07 | Chiron Corporation | Compositions and methods for generating an immune response utilizing alphavirus-based vector systems |
DE60135983D1 (de) * | 2000-05-31 | 2008-11-13 | Novartis Vaccines & Diagnostic | Verfahren zur reinigung von alphaviralen replikon partikeln |
WO2002000174A2 (en) | 2000-06-28 | 2002-01-03 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of lung cancer |
US6783939B2 (en) | 2000-07-07 | 2004-08-31 | Alphavax, Inc. | Alphavirus vectors and virosomes with modified HIV genes for use in vaccines |
AU2001290642A1 (en) * | 2000-09-07 | 2002-03-22 | University Of North Carolina At Chapel Hill | Vectors derived from south african arbovirus no. 86 |
WO2002089747A2 (en) | 2001-05-09 | 2002-11-14 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of prostate cancer |
US20030077251A1 (en) * | 2001-05-23 | 2003-04-24 | Nicolas Escriou | Replicons derived from positive strand RNA virus genomes useful for the production of heterologous proteins |
JP4790984B2 (ja) * | 2001-09-06 | 2011-10-12 | アルファヴァックス,インコーポレイテッド | アルファウイルスレプリコンベクター系 |
AU2002365279B2 (en) | 2001-12-17 | 2009-08-13 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of inflammatory bowel disease |
EP1585812B1 (de) | 2002-12-13 | 2017-01-18 | Alphavax, Inc. | Multiantigene alphavirusrepliconpartikel und verfahren |
ES2630222T3 (es) | 2002-12-13 | 2017-08-18 | Alphavax, Inc. | Partículas alfavíricas y métodos de preparación |
ZA200505302B (en) | 2003-01-06 | 2007-03-28 | Corixa Corp | Certain aminoalkyl glucosaminide phosphate compounds and their use |
US7960522B2 (en) | 2003-01-06 | 2011-06-14 | Corixa Corporation | Certain aminoalkyl glucosaminide phosphate compounds and their use |
MXPA05010007A (es) * | 2003-03-20 | 2006-03-10 | Alphavax Inc | Replicones de alfavirus y construcciones auxiliares mejorados. |
EP1651666B1 (de) * | 2003-07-11 | 2009-05-27 | Alphavax, Inc. | Cytomegalovirusimpfstoffe, die auf dem alphavirus basieren |
US8574590B2 (en) | 2003-07-30 | 2013-11-05 | Integral Molecular, Inc. | Lipoparticles comprising proteins, methods of making, and using the same |
PT1751289E (pt) | 2004-05-18 | 2009-03-31 | Alphavax Inc | Vectores de alfavirais derivados da tc-83, partículas e métodos |
CA2567446C (en) * | 2004-05-21 | 2018-01-02 | Chiron Corporation | Alphavirus vectors for respiratory pathogen vaccines |
AU2005327198B2 (en) * | 2004-07-09 | 2011-03-31 | University Of North Carolina At Chapel Hill | Viral adjuvants |
US20080085289A1 (en) | 2004-09-22 | 2008-04-10 | Cindy Castado | Immunogenic Composition |
AU2006302794B2 (en) * | 2005-02-15 | 2011-08-04 | Children's Hospital, Inc. | New live virus vaccines |
WO2007120368A2 (en) | 2006-01-09 | 2007-10-25 | The Regents Of The University Of California | Immunostimulatory combinations for vaccine adjuvants |
NZ575901A (en) | 2006-09-12 | 2012-04-27 | Alphavax Inc | Alphavirus replicon particles matched to protein antigens as immunological adjuvants |
CA2668417A1 (en) * | 2006-11-03 | 2008-05-15 | Alphavax, Inc. | Alphavirus and alphavirus replicon particle formulations and methods |
ES2588906T3 (es) * | 2007-06-21 | 2016-11-07 | Alphavax, Inc. | Casetes sin promotor para la expresión de proteínas estructurales de alfavirus |
WO2010065414A1 (en) | 2008-12-01 | 2010-06-10 | Alphavax, Inc. | Use of micrornas to control virus helper nucleic acids |
WO2010118244A1 (en) | 2009-04-08 | 2010-10-14 | Alphavax, Inc. | Alphavirus Replicon Particles Expressing TRP2 |
JP2013506681A (ja) * | 2009-10-02 | 2013-02-28 | バクスター・インターナショナル・インコーポレイテッド | 腎損傷の処置における使用のための造血幹細胞 |
US9422529B2 (en) | 2010-12-22 | 2016-08-23 | The Board Of Regents Of The University Of Texas System | Alphavirus compositions and methods of use |
WO2012088473A1 (en) * | 2010-12-22 | 2012-06-28 | The Board Of Regents Of The University Of Texas System | Alphavirus compositions and methods of use |
MX2013013627A (es) | 2011-06-21 | 2014-04-25 | Oncofactor Corp | Composiciones y metodos para la terapia y diagnostico de cancer. |
US20130216495A1 (en) | 2012-02-21 | 2013-08-22 | Baxter Healthcare Sa | Pharmaceutical composition comprising cd34+ cells |
CA2873964A1 (en) | 2012-05-21 | 2013-11-28 | Steven F. Dowdy | Generation of human ips cells by a synthetic self-replicative rna |
WO2016154010A1 (en) | 2015-03-20 | 2016-09-29 | Makidon Paul | Immunogenic compositions for use in vaccination against bordetella |
WO2016204983A1 (en) * | 2015-06-19 | 2016-12-22 | Seracare Life Sciences, Inc. | Sindbis control virus |
EP3403660A4 (de) * | 2016-01-14 | 2019-08-21 | Industry - University Cooperation Foundation Hanyang University | Verfahren mit verwendung der expression von lin28 zur verwendung von stammzellen mit ausgezeichneter erneuerbarkeit und differenzierungspotenzial |
GB201603374D0 (en) * | 2016-02-26 | 2016-04-13 | Ucl Business Plc | Packaging cell |
US11285191B2 (en) | 2016-07-26 | 2022-03-29 | The Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Immunostimulatory compositions and uses therefor |
CN111491655A (zh) | 2017-08-07 | 2020-08-04 | 加利福尼亚大学董事会 | 用于生成安全细胞治疗剂的平台 |
US10960071B2 (en) | 2017-08-07 | 2021-03-30 | The Regents Of The University Of California | Platform for generating safe cell therapeutics |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4650764A (en) * | 1983-04-12 | 1987-03-17 | Wisconsin Alumni Research Foundation | Helper cell |
US5091309A (en) | 1986-01-16 | 1992-02-25 | Washington University | Sindbis virus vectors |
US5217879A (en) * | 1989-01-12 | 1993-06-08 | Washington University | Infectious Sindbis virus vectors |
US5185440A (en) * | 1989-06-20 | 1993-02-09 | North Carolina State University | cDNA clone coding for Venezuelan equine encephalitis virus and attenuating mutations thereof |
SE9003978D0 (sv) * | 1990-12-13 | 1990-12-13 | Henrik Garoff | Dna expressionssystem baserade paa ett virus replikon |
US6156304A (en) | 1990-12-20 | 2000-12-05 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Gene transfer for studying and treating a connective tissue of a mammalian host |
US6015686A (en) | 1993-09-15 | 2000-01-18 | Chiron Viagene, Inc. | Eukaryotic layered vector initiation systems |
ATE437942T1 (de) * | 1993-09-15 | 2009-08-15 | Novartis Vaccines & Diagnostic | Rekombinante alphavirus-vektoren |
SE9401091D0 (sv) * | 1994-03-31 | 1994-03-31 | Bioption Ab | Alphavirus cDNA vectors |
SE9401709D0 (sv) | 1994-05-18 | 1994-05-18 | Mathilda Sjoeberg | Improved alphavirus vectors for expression of heterologous DNA |
US5505947A (en) | 1994-05-27 | 1996-04-09 | The University Of North Carolina At Chapel Hill | Attenuating mutations in Venezuelan Equine Encephalitis virus |
AU4594996A (en) | 1994-11-30 | 1996-06-19 | Chiron Viagene, Inc. | Recombinant alphavirus vectors |
US5792462A (en) * | 1995-05-23 | 1998-08-11 | University Of North Carolina At Chapel Hill | Alphavirus RNA replicon systems |
US5639650A (en) * | 1995-05-23 | 1997-06-17 | The University Of North Carolina At Chapel Hill | cDNA clone for South African Arbovirus No. 86 |
EP1997900A3 (de) * | 1996-04-05 | 2010-10-06 | Novartis Vaccines and Diagnostics, Inc. | Rekombinante Vektoren auf Alphavirus-Basis mit reduzierter Hemmung der zellulären Makromolekularsynthese |
-
1997
- 1997-02-19 US US08/801,263 patent/US5811407A/en not_active Expired - Lifetime
-
1998
- 1998-02-18 AT AT98906462T patent/ATE419368T1/de not_active IP Right Cessation
- 1998-02-18 JP JP53676098A patent/JP2001515348A/ja active Pending
- 1998-02-18 WO PCT/US1998/002945 patent/WO1998036779A2/en active IP Right Grant
- 1998-02-18 CA CA2281858A patent/CA2281858C/en not_active Expired - Fee Related
- 1998-02-18 US US09/367,764 patent/US6583121B1/en not_active Expired - Lifetime
- 1998-02-18 EP EP98906462A patent/EP0989863B1/de not_active Expired - Lifetime
- 1998-02-18 DE DE69840403T patent/DE69840403D1/de not_active Expired - Lifetime
- 1998-02-18 AU AU61682/98A patent/AU749903B2/en not_active Ceased
- 1998-06-22 US US09/102,248 patent/US6008035A/en not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
US6008035A (en) | 1999-12-28 |
AU6168298A (en) | 1998-09-09 |
ATE419368T1 (de) | 2009-01-15 |
WO1998036779A2 (en) | 1998-08-27 |
JP2001515348A (ja) | 2001-09-18 |
AU749903B2 (en) | 2002-07-04 |
CA2281858C (en) | 2011-01-25 |
WO1998036779A3 (en) | 1999-04-22 |
US5811407A (en) | 1998-09-22 |
US6583121B1 (en) | 2003-06-24 |
EP0989863B1 (de) | 2008-12-31 |
CA2281858A1 (en) | 1998-08-27 |
EP0989863A2 (de) | 2000-04-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE69840403D1 (de) | System zum transfer und zur expression von heterologen genen ins knochenmark in vivo | |
CN105821039B (zh) | 联合免疫基因抑制HBV复制的特异性sgRNA、表达载体及其应用 | |
Luytjes et al. | Sequence of mouse hepatitis virus A59 mRNA 2: indications for RNA recombination between coronaviruses and influenza C virus | |
CN103930551B (zh) | 猴腺病毒和杂合腺病毒载体 | |
RU2233333C2 (ru) | Вирусные векторы и их применение в генной терапии | |
Lipskaya et al. | Frequent isolation of intertypic poliovirus recombinants with serotype 2 specificity from vaccine‐associated polio cases | |
RU95122419A (ru) | Вирусные векторы и их применение в генной терапии | |
MXPA02005525A (es) | Clones infecciosos. | |
HU229101B1 (en) | Dna transfection system for the generation of infectious influenza virus | |
EP1736539A1 (de) | Abgeschwächte SARS-CoV Impfstoffe | |
CA2447450A1 (en) | Corona-virus-like particles comprising functionally deleted genomes | |
DE69737886D1 (de) | Infektioese rna virus-klone, vakzine und davon abgeleitete diagnostische assays | |
ATE205537T1 (de) | Verwendung von plasmiden zur herstellung eines impfstoffs bei mensch und tier | |
DE69534600D1 (de) | Nukleotid- und aminosäuresequenzen der gene des hüllproteins 1 und des kernproteins von hepatitis c virus | |
ATE101200T1 (de) | Impfstoffe gegen menschliche respiratorische viren. | |
UA84667C2 (ru) | Вакцина, направленная против инфекции, вызванной вирусом герпеса болезни марека | |
HU228469B1 (en) | Attenuated pestiviruses, their use, and nuclein acids for their production | |
RU2002100209A (ru) | Gm-csf лошади | |
ATE366819T1 (de) | Genetische immunisierung gegen zervixkarzinom | |
Prockop | Targeting gene therapy for osteogenesis imperfecta | |
PT1009768E (pt) | Persefina e factores de crescimento relacionados | |
US20060171962A1 (en) | SARS vaccine | |
HUP0200320A2 (hu) | Macskaeredetű CD28-at, CD80-at, CD86-ot vagy CTL4-A-t expresszáló rekombináns vírusok és alkalmazásuk | |
EP4172329A2 (de) | Zusammensetzungen zur genomeditierung und verfahren zur verwendung davon | |
DE60140950D1 (de) | Neuer gentherapeutischer wirkstoff zur behandlung g |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8364 | No opposition during term of opposition |